NCT07293559 Understanding Practices of Lactation and Infant Feeding Together With Women With HIV in the United States
| NCT ID | NCT07293559 |
| Status | Recruiting |
| Phase | — |
| Sponsor | International Maternal Pediatric Adolescent AIDS Clinical Trials Group |
| Condition | HIV-1-infection |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,150 participants |
| Start Date | 2026-02-24 |
| Primary Completion | 2031-04-24 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,150 participants in total. It began in 2026-02-24 with a primary completion date of 2031-04-24.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
IMPAACT 2046/UPLIFT (Understanding Practices of Lactation and Infant Feeding decisions Together with women with HIV) is a multi-site, mixed-methods, observational cohort study. The purpose of the study is to explore infant feeding preferences, practices, and outcomes among mothers with HIV and their families in the United States. It will employ both qualitative and quantitative research methods to address existing knowledge gaps and to understand the clinical, behavioral, and social factors influencing infant feeding decisions. As part of the study's mixed method approach, a longitudinal cohort study of mothers and their infants will be established. The study also aims to pilot a national registry of breastfeeding women living with HIV in the United States.
Eligibility Criteria
Core Activity 1 Inclusion Criteria: Pregnant and Postpartum Women with HIV * Is of legal age or circumstance to provide independent informed consent * Belongs to one of the following five categories: * Is pregnant with a gestational age of 28 0/7 to 37 6/7 weeks at entry and is considering breastfeeding * Is pregnant with a gestational age of 28 0/7 to 37 6/7 weeks at entry and is not considering breastfeeding * Gave birth to a live born infant after 28 February 2023, is over 4 weeks postpartum, did not breastfeed for any duration and has no intent to breastfeed * Gave birth to a live born infant after 28 February 2023, is over 4 weeks postpartum, breastfed for less than four weeks, and has weaned * Gave birth to a live born infant after 28 February 2023, is over 4 weeks postpartum, and breastfed for four weeks or longer * Diagnosed with HIV prior to or during the pregnancy * If preferred language is other than English, is willing to participate in interviews with an available translator. Core Activity 1 Inclusion Criteria: Healthcare Providers and Ancillary Healthcare Professionals * Is of legal age or circumstance to provide independent informed consent * Is a healthcare provider who self-identifies as an obstetrician, midwife, nurse, adult or pediatric infectious disease specialist, or advance practice provider who participated in the care of at least five PPWH and/or their infants over the three years prior to entry OR * Is an ancillary healthcare professional who self-identifies as a social worker, lactation support provider, patient navigator, pharmacist, doula who participated in the care of at least five PPWH and/or their infants over the three years prior to entry Core Activity 1 Inclusion Criteria: Influential Individuals * Has been identified by a PPWH enrolled in Core Activity 1 as aware of her HIV status and contributing to her infant feeding decisions * Is of legal age or circumstance to provide independent informed consent * If preferred language is other than English, is willing to participate in interviews with an available translator. Core Activity 2 Inclusion Criteria: Pregnant and Postpartum Women with HIV and their Infant * Is of legal age or circumstance to provide independent informed consent * Is pregnant with singleton fetus with a gestational age of ≥ 28 0/7 weeks at entry OR * Gave birth to a live born, singleton infant up to 7 days prior to entry * Diagnosed with HIV prior to or during the pregnancy * Expected to be available for the duration of follow-up Core Activity 3 Inclusion Criteria: Breastfeeding Postpartum Women with HIV and their Infant * Is of legal age or circumstance to provide independent informed consent * Must be up to 7 days postpartum with live-born infant * Diagnosed with HIV prior to or during the pregnancy * Breastfed her infant for any duration Core Activity 3 Inclusion Criteria: Pilot Registry Testers * Is of legal age or circumstance to provide independent informed consent * Working at a healthcare facility that provides care for women with HIV who are breastfeeding and/or their infants Exclusion Criteria: Core Activities 1-3 * Has any condition identified during the screening period that, in the opinion of site investigator, would preclude informed consent, make study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives
Contact & Investigator
Lisa Abuogi
STUDY CHAIR
University of Colorado, Denver
Frequently Asked Questions
Who can join the NCT07293559 clinical trial?
This trial is open to participants of all sexes, studying HIV-1-infection. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07293559 currently recruiting?
Yes, NCT07293559 is actively recruiting participants. Contact the research team at llevy@fhi360.org for enrollment information.
Where is the NCT07293559 trial being conducted?
This trial is being conducted at Los Angeles, United States, Los Angeles, United States, San Diego, United States, Aurora, United States and 7 additional locations.
Who is sponsoring the NCT07293559 clinical trial?
NCT07293559 is sponsored by International Maternal Pediatric Adolescent AIDS Clinical Trials Group. The principal investigator is Lisa Abuogi at University of Colorado, Denver. The trial plans to enroll 1,150 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.